Novartis AG (NYSE:NVS) saw an uptick in trading volume on Thursday . 1,075,652 shares traded hands during trading, a decline of 3% from the previous session’s volume of 1,104,592 shares.The stock last traded at $80.04 and had previously closed at $80.30.

Several analysts have commented on the stock. Leerink Swann reissued a “hold” rating on shares of Novartis AG in a research report on Monday, May 2nd. Bank of America Corp. reaffirmed a “hold” rating on shares of Novartis AG in a report on Wednesday, May 18th. Jefferies Group reaffirmed a “buy” rating on shares of Novartis AG in a report on Friday, May 13th. Citigroup Inc. reaffirmed a “neutral” rating on shares of Novartis AG in a report on Tuesday, May 24th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novartis AG in a report on Thursday, May 26th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $91.20.

The firm has a market capitalization of $189.43 billion and a P/E ratio of 28.40. The stock’s 50-day moving average price is $82.20 and its 200 day moving average price is $77.44.

Novartis AG (NYSE:NVS) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.18 by $0.05. During the same quarter last year, the business earned $1.25 earnings per share. The business earned $12.47 billion during the quarter, compared to analyst estimates of $12.33 billion. On average, equities analysts forecast that Novartis AG will post $4.73 earnings per share for the current year.

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.